Spots Global Cancer Trial Database for αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
Official Title: An Exploratory Study of αPD1-MSLN-CAR T Cells Secreting PD-1 Nanobodies for the Treatment of MSLN-positive Advanced Solid Tumors
Study ID: NCT04503980
Interventions
Study Description
Brief Summary: This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies (αPD1-MSLN-CAR T cells) in patients with solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shanghai Tenth people's Hospital, Shanghai, Shanghai, China
Contact Details
Name: Qing Qu
Affiliation: Shanghai 10th People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
